KR20130130730A - 알콕시이미다졸-1-일메틸 비페닐 카복실산의 결정형 - Google Patents

알콕시이미다졸-1-일메틸 비페닐 카복실산의 결정형 Download PDF

Info

Publication number
KR20130130730A
KR20130130730A KR1020137014134A KR20137014134A KR20130130730A KR 20130130730 A KR20130130730 A KR 20130130730A KR 1020137014134 A KR1020137014134 A KR 1020137014134A KR 20137014134 A KR20137014134 A KR 20137014134A KR 20130130730 A KR20130130730 A KR 20130130730A
Authority
KR
South Korea
Prior art keywords
crystalline
salt
hemiedylate
ethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020137014134A
Other languages
English (en)
Korean (ko)
Inventor
폴 알. 파더리
벤캣 알. 탈라디
Original Assignee
세라밴스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 세라밴스 인코포레이티드 filed Critical 세라밴스 인코포레이티드
Publication of KR20130130730A publication Critical patent/KR20130130730A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020137014134A 2010-11-10 2011-11-09 알콕시이미다졸-1-일메틸 비페닐 카복실산의 결정형 Withdrawn KR20130130730A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41201110P 2010-11-10 2010-11-10
US61/412,011 2010-11-10
PCT/US2011/059895 WO2012064807A1 (en) 2010-11-10 2011-11-09 Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid

Publications (1)

Publication Number Publication Date
KR20130130730A true KR20130130730A (ko) 2013-12-02

Family

ID=45003086

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137014134A Withdrawn KR20130130730A (ko) 2010-11-10 2011-11-09 알콕시이미다졸-1-일메틸 비페닐 카복실산의 결정형

Country Status (19)

Country Link
US (3) US8362060B2 (https=)
EP (1) EP2638017B1 (https=)
JP (2) JP2013542258A (https=)
KR (1) KR20130130730A (https=)
CN (1) CN103189362B (https=)
AR (1) AR083828A1 (https=)
AU (1) AU2011326622B2 (https=)
BR (1) BR112013011715A2 (https=)
CA (1) CA2812598A1 (https=)
CO (1) CO6741224A2 (https=)
ES (1) ES2567721T3 (https=)
IL (1) IL225303A0 (https=)
MX (1) MX2013005165A (https=)
NZ (1) NZ609804A (https=)
PH (1) PH12013500945A1 (https=)
RU (1) RU2013126403A (https=)
SG (1) SG189448A1 (https=)
TW (1) TW201300366A (https=)
WO (1) WO2012064807A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI448284B (zh) 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
CN106810542B (zh) * 2015-11-30 2021-03-09 苏州开拓药业股份有限公司 一种硫代咪唑烷酮化合物的晶型、盐型及其制备方法
EP4337638A1 (en) * 2021-05-11 2024-03-20 Astex Pharmaceuticals, Inc. Solid forms of salts of 4-[5-[(3s)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-ethylpropyl)phenyl]phenyl]-2-fluoro-benzonitrile

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006027680A1 (en) 2004-09-10 2006-03-16 Pfizer Limited 3-(1-carbamoylcyclohexyl) propionic acid derivatives as inhibitors of neutral endopeptidase enzyme
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2007106708A2 (en) 2006-03-10 2007-09-20 Novartis Ag Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
TWI448284B (zh) * 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TW201014830A (en) * 2008-09-30 2010-04-16 Theravance Inc Crystalline form of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
TWI545114B (zh) * 2009-09-29 2016-08-11 施萬生物製藥研發Ｉｐ有限責任公司 製備聯苯基咪唑化合物之方法
US8399501B2 (en) 2010-03-04 2013-03-19 Theravance, Inc. Crystalline alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid and methods for preparing thereof

Also Published As

Publication number Publication date
AR083828A1 (es) 2013-03-27
BR112013011715A2 (pt) 2017-10-31
CO6741224A2 (es) 2013-08-30
PH12013500945A1 (en) 2013-07-08
TW201300366A (zh) 2013-01-01
AU2011326622B2 (en) 2014-12-18
HK1187919A1 (zh) 2014-04-17
EP2638017B1 (en) 2016-01-27
RU2013126403A (ru) 2014-12-20
US20120115920A1 (en) 2012-05-10
JP2016028061A (ja) 2016-02-25
MX2013005165A (es) 2013-07-05
US9249105B2 (en) 2016-02-02
US8362060B2 (en) 2013-01-29
US20130267573A1 (en) 2013-10-10
ES2567721T3 (es) 2016-04-26
JP2013542258A (ja) 2013-11-21
CN103189362A (zh) 2013-07-03
NZ609804A (en) 2015-02-27
CA2812598A1 (en) 2012-05-18
AU2011326622A1 (en) 2013-04-04
US20150133518A1 (en) 2015-05-14
IL225303A0 (en) 2013-06-27
WO2012064807A1 (en) 2012-05-18
US8802709B2 (en) 2014-08-12
CN103189362B (zh) 2015-03-11
EP2638017A1 (en) 2013-09-18
SG189448A1 (en) 2013-05-31

Similar Documents

Publication Publication Date Title
US11033533B2 (en) (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
KR102640906B1 (ko) 네프릴리신 저해제로서 (2s,4r)-5-(5''-클로로-2''-플루오로비페닐-4-일)-4-(에톡시옥살릴아미노)-2-히드록시메틸-2-메틸펜타노익산
JP5495396B2 (ja) アルコキシイミダゾール−１−イルメチルビフェニルカルボン酸の結晶形
US11718591B2 (en) Crystalline (2S,4R)-5-(5′-chloro-2′-fluoro-[1,1′-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2- methylpentanoic acid and uses thereof
US9249105B2 (en) Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
TW201336839A (zh) （２ｓ，４ｒ）－５－聯苯－４－基－２－羥甲基－２－甲基－４－［（１ｈ－［１，２，３］三唑－４－羰基）－胺基］－戊酸５－甲基－２－酮基－［１，３］二氧雜環戊烯－４－基甲酯之結晶型
US9271965B2 (en) Crystalline forms of (R)-3-[N-(3'-chlorobiphenyl-4-ylmethyl)-N'-(3-hydroxyisoxazole-5-carbonyl)hydrazino]-2-hydroxyproprionic acid isopropyl ester
HK1187919B (en) Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20130531

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20140729

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid